Paroxetine low-dose - Noven Therapeutics

Drug Profile

Paroxetine low-dose - Noven Therapeutics

Alternative Names: Brisdelle; LDMP; Low-dose mesylate salt of paroxetine; Mesafem; Paroxetine mesylate

Latest Information Update: 16 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synthon Pharmaceuticals Ltd
  • Developer Noven Therapeutics
  • Class Antidepressants; Anxiolytics; Benzodioxoles; Fluorobenzenes; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Oct 2014 Adverse events data from two phase III studies in Vasomotor symptoms released by Noven Pharmaceuticals
  • 13 Jan 2014 Noven Pharmaceuticals and Shionogi agree to co-promote low-dose paroxetine in USA for Vasomotor symptoms
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top